Balyasny Asset Management
VC Fund
Chicago, United States
Balyasny Asset Management (BAM) is a diversified global investment firm founded in 2001 by Dmitry Balyasny, Scott Schroeder, and Taylor O'Malley. With over $37 billion in assets under management, BAM employs more than 2,800 people across 24 offices in the U.S. and Canada, Europe, the Middle East, and Asia. The firm’s investment teams span five strategies, including Equities Long/Short, Fixed Income & Macro, Commodities, Multi-Asset Arbitrage, and Systematic. Balyasny’s mission is to deliver to its investors absolute, uncorrelated returns in all market environments.
- Total investments:
- 56
- Last investment:
- Lead investor:
- 9%
- Fund size:
- $2.5M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Balyasny Asset Management invests in
Stages Balyasny Asset Management invests in
Countries Balyasny Asset Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Series A
- $6.1M–$179M
- Series D
- $35M–$225M
- Post-IPO Equity
- $35M–$197M
Investment Focus
Industry
- Biotechnology 28 (50%)
- Health Care 17 (30%)
- Pharmaceutical 12 (21%)
- Biopharma 11 (20%)
- Therapeutics 9 (16%)
Stage
- Post-IPO Equity 18 (32%)
- Series A 8 (14%)
- Series D 7 (13%)
- Series C 5 (9%)
- Series B 3 (5%)
Country
- United States 41 (73%)
- China 3 (5%)
- Latvia 1 (2%)
- Sweden 1 (2%)
- Belgium 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Michael Magnell
Senior Analyst
|
Senior Analyst | Total investments: 0 | Find email | |
|
Brad Downes
Associate Director - Strategic Finance
|
Associate Director - Strategic Finance | Total investments: 0 | Find email | |
|
David Black
Managing Director Business Development
|
Managing Director Business Development | Total investments: 0 | Find email | |
|
David Shaw
Senior Analyst
|
Senior Analyst | Total investments: 0 | Find email | |
|
Douglas Cilento
Head of Macro Trading
|
Head of Macro Trading | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kalshi is a federally regulated financial exchange that allows investors to trade directly on the anticipated outcome of future events. Kalshi’s markets cover a wide range of topics including economics, international affairs, media and entertainment, climate/weather, and public health. Because Kalshi’s market topics can be more specific thanother instruments like stocks or bonds, investors can get direct exposure to the events and trends that they are interested in. For example, a Kalshi market on whether a certain free trade agreement will be signed can help retail investors get exposure to emerging markets and fluctuations in international trade.Website: https://kalshi.com | $1B / Series G / Oct 29, 2026 | ||
| Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broadpipeline of innovative drug candidates.They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China.Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions. | $250M / Post-IPO Equity / Oct 22, 2026 | ||
| Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $135M / Series B / Oct 13, 2026 | ||
| Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with thegoal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. | $150M / Post-IPO Equity / Aug 21, 2026 | ||
| Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $132M / Post-IPO Equity / Jul 16, 2026 | ||
| Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | ||
| Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. | $32.5M / Series A / Jun 01, 2026 | ||
| Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | ||
| Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $35M / Post-IPO Equity / May 05, 2026 | ||
| Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | ||
| See all 56 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Balyasny Asset Management invest in?
Balyasny Asset Management invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Series A stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Balyasny Asset Management invest in?
Balyasny Asset Management typically joins rounds of $6.1M–$179M at Series A, $35M–$225M at Series D and $35M–$197M at Post-IPO Equity. These are whole funding-round sizes, not Balyasny Asset Management's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Balyasny Asset Management took part in.
How do I contact Balyasny Asset Management?
Public channels for Balyasny Asset Management include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Balyasny Asset Management?
The team at Balyasny Asset Management includes Michael Magnell (Senior Analyst), Brad Downes (Associate Director - Strategic Finance) and David Black (Managing Director Business Development), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!